LungLife AI, INC CPT(R) Code granted by American Medical Association (2499X)
January 04 2022 - 2:00AM
UK Regulatory
TIDMLLAI
RNS Number : 2499X
LungLife AI, INC
04 January 2022
LungLife AI, Inc.
(the "Company" or "LungLife")
CPT(R) Code granted by American Medical Association
Successful grant marks first step facilitating commercial
reimbursement
LungLife AI (AIM: LLAI), a developer of clinical diagnostic
solutions for lung cancer announces it has been granted a CPT(R)
Proprietary Laboratory Analyses (PLA) code for its LungLB(R) test
by the American Medical Association (AMA). The new code has been
approved and published by the AMA Editorial Panel and is scheduled
to become effective on 1 April 2022.
Reimbursement in the US is comprised of three components: code,
price, and coverage. CPT(R) codes offer health care professionals a
uniform language for coding medical services and procedures, and
the CPT(R) code allows clinical laboratories to more specifically
identify their tests when billing Medicare and commercial insurers.
The successful granting of a CPT(R) code marks the first step on
the path for commercial reimbursement.
Paul Pagano , Chief Executive Officer, LungLife AI said: "A
CPT(R) code is fundamental in the commercialisation of the
LungLB(R) test. We were delighted with the AMA's decision as this
will facilitate access to LungLB(R) for patients with indeterminate
pulmonary nodules who are at-risk for lung cancer."
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com
Paul Pagano, CEO Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser Tel: +44 (0)20 7597 5970
& Broker)
Daniel Adams / Virginia Bull / Cameron
MacRitchie
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
Paul McManus / Alice Woodings Mob: 07980 541 893 / 07407 804 654
About LungLife AI
LungLife is a developer of clinical diagnostic solutions for
lung cancer enhanced by artificial intelligence. The Company's
diagnostic solutions are designed to make a significant impact in
the early detection of lung cancer.
The Company's technology is a combination of the recovery of
rare cells and blood-based biomarkers shown to be altered in lung
cancer. The Company employs machine learning to improve biomarker
detection, and intends to build a deep, novel pool of lung
cancer-related data for AI-enabled applications designed to improve
its diagnostic solutions over time.
The Company's core technologies are integrated in the LungLB(R)
test, which is intended to be used as a tool to provide physicians
with additional information to help in the decision-making process
for people with indeterminate lung nodules that may be lung cancer
following a CT scan. There are estimated to be over 1.5 million
individuals with indeterminate lung nodules diagnosed each year in
the United States. The LungLB(R) test may have additional
utilities, the most significant of which is likely to be in
monitoring individuals for recurrence following surgical removal of
cancerous lung nodules.
The Company has completed a 149 subject pilot study to evaluate
the LungLB(R) test, which showed a well-balanced performance and a
Positive Predictive Value of 89 per cent. The Company is now
gearing up to proceed to a larger, multi-centre validation study to
garner regulatory and reimbursement support and facilitate
commercialisation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
REABCGDBSGGDGDX
(END) Dow Jones Newswires
January 04, 2022 02:00 ET (07:00 GMT)
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From May 2024 to Jun 2024
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From Jun 2023 to Jun 2024